ArticleThe Journal of allergy and clinical immunology2014
Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).
Article in The Journal of allergy and clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 244 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
244 citing papers in PubMed, 1 synthesis or guideline pooled it, 479 citations in OpenAlex.
- Positive rate of wheat allergens in the Chinese allergic population: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Peanut allergy oral immunotherapy drives single-cell multi-omic changes in peanut-reactive T cells associated with sustained unresponsiveness.Nature immunology · 2025Trial
- HLA-DRAllergy · 2025Trial
- CD8Nature communications · 2022Trial
- Maximum Dose Food Challenges Reveal Transient Sustained Unresponsiveness in Peanut Oral Immunotherapy (POIMD Study).The journal of allergy and clinical immunology. In practice · 2022Trial
- Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells.The Journal of clinical investigation · 2022Trial
- Memory and naïve gamma delta regulatory T-cell gene expression in the first 24-weeks of peanut oral immunotherapy.Clinical immunology (Orlando, Fla.) · 2021Trial
- Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.The Journal of allergy and clinical immunology · 2020Trial
- Trial
- Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.The Journal of allergy and clinical immunology · 2019Trial
- Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.Lancet (London, England) · 2019Trial
- Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles.The Journal of allergy and clinical immunology · 2019Trial
- Randomized controlled trial on the influence of dietary intervention on epigenetic mechanisms in children with cow's milk allergy: the EPICMA study.Scientific reports · 2019Trial
- High- and low-dose oral immunotherapy similarly suppress pro-allergic cytokines and basophil activation in young children.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019Trial
- Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.The Journal of allergy and clinical immunology · 2017Trial
- Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.The Journal of allergy and clinical immunology · 2017Trial
- Omalizumab facilitates rapid oral desensitization for peanut allergy.The Journal of allergy and clinical immunology · 2017Trial
- Trial
- Coordinated changes in oral propionate, oral microbiota, and peripheral blood inflammatory processes during peanut oral immunotherapy.The Journal of allergy and clinical immunology · 2026Article
- Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets.MedComm · 2026Review
184 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe mechanisms contributing to clinical immune tolerance remain incompletely understood. This study provides evidence for specific immune mechanisms that are associated with a model of operationally defined clinical tolerance.
objectiveOur overall objective was to study laboratory changes associated with clinical immune tolerance in antigen-induced T cells, basophils, and antibodies in subjects undergoing oral immunotherapy (OIT) for peanut allergy.
methodsIn a phase 1 single-site study, we studied participants (n = 23) undergoing peanut OIT and compared them with age-matched allergic control subjects (n = 20) undergoing standard of care (abstaining from peanut) for 24 months. Participants were operationally defined as clinically immune tolerant (IT) if they had no detectable allergic reactions to a peanut oral food challenge after 3 months of therapy withdrawal (IT, n = 7), whereas those who had an allergic reaction were categorized as nontolerant (NT; n = 13).
resultsAntibody and basophil activation measurements did not statistically differentiate between NT versus IT participants. However, T-cell function and demethylation of forkhead box protein 3 (FOXP3) CpG sites in antigen-induced regulatory T cells were significantly different between IT versus NT participants. When IT participants were withdrawn from peanut therapy for an additional 3 months (total of 6 months), only 3 participants remained classified as IT participants, and 4 participants regained sensitivity along with increased methylation of FOXP3 CpG sites in antigen-induced regulatory T cells.
conclusionIn summary, modifications at the DNA level of antigen-induced T-cell subsets might be predictive of a state of operationally defined clinical immune tolerance during peanut OIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.